Overview

Safety, Pharmacokinetics, and Pharmacodynamics of ARC1779 in Healthy Volunteers

Status:
Completed
Trial end date:
2007-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to establish the overall safety and tolerability of ARC1779 in healthy volunteers, and to characterize its pharmacokinetic and pharmacodynamic profile with respect to parameters of platelet function and von Willebrand Factor activity.
Phase:
Phase 1
Details
Lead Sponsor:
Archemix Corp.